GlassScriptPhysician profile
Dana L Willerton
NPI 1639406424
$1,939.64
in general payments reported to CMS, 2019-2025
23 companies · $32.06 in 2025
The $32.06 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $409 · 2022: $728 · 2023: $479 · 2024: $291 · 2025: $32.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.31 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $268.12 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $152.59 | 2021-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $109.46 | 2021-2023 | |
| Janssen Biotech, INC. | $92.02 | 2021-2022 | |
| Ucb, INC. | $86.25 | 2021-2024 | Cimzia, Bimzelx |
| Revance Therapeutics, INC. | $84.84 | 2024 | Daxxify |
| Sun Pharmaceutical Industries INC. | $82.90 | 2021-2022 | |
| Pfizer INC. | $74.97 | 2021-2024 | |
| Epi Health, LLC | $65.93 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.47 | 2023-2024 | Jublia, Arazlo, Duobrii |
| Amgen INC. | $43.57 | 2021-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $43.34 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $41.59 | 2021 | |
| Galderma Laboratories, L.P. | $31.97 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $27.96 | 2022 | |
| Mayne Pharma Commercial LLC | $23.48 | 2022-2023 | |
| Biofrontera INC. | $20.20 | 2021 | |
| Incyte Corporation | $16.76 | 2021 | |
| Verrica Pharmaceuticals INC. | $14.98 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $14.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.04 | 2021 | |
| Genzyme Corporation | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Willerton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.